Status:
UNKNOWN
RIC Regimen for Low- and Intermediate-risk MDS Receiving Haplo-HSCT
Lead Sponsor:
Peking University People's Hospital
Conditions:
Myelodysplastic Syndromes
Eligibility:
All Genders
1-70 years
Phase:
PHASE2
Brief Summary
This study aimed to evaluate the efficacy of reduced intensity conditioning (RIC) regimen in low- and intermediate-risk myelodysplastic syndrome (MDS) patients who receive haploidentical hematopoietic...
Detailed Description
RIC regimen was given for low and intermediate MDS patients who would receive haplo-HSCT. The primary end point was transplant-related mortality. The secondary end points were overall survival, diseas...
Eligibility Criteria
Inclusion
- Patients who had low- and intermediate-risk MDS without ISD nor URD receiving haploidentical hematopoietic stem cell transplantation
Exclusion
- Patients having ISD or URD; patients having high-risk MDS; patients with active infection; patients with poor compliance; patients with organ failure
Key Trial Info
Start Date :
February 1 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2023
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT03412266
Start Date
February 1 2018
End Date
March 1 2023
Last Update
April 20 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking University Institute of Hematology,Beijing
Beijing, Beijing Municipality, China, 100044